From today (September 1), patients with melanoma have access to breakthrough medicine Keytruda (pembrolizumab),…
MRV Research
Combination of Roche medicines Cotellic and Zelboraf approved in Switzerland for the treatment of patients with advanced melanoma
Roche has announced that the Swiss licensing and supervisory authority for therapeutic products (Swissmedic) has approved combination therapy with Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of patients with advanced melanoma. This makes Switzerland the first country where this combination therapy is available to patients
Multiple primary melanomas most likely in first year after initial melanoma diagnosis
The risk for multiple primary melanomas was greatest in the first year after initial melanoma diagnosis, with patients who were older, male, white and partnered being at higher risk, according to recently published study results
The Lymphoma-Melanoma Connection
Researchers have for the first time shown that older patients with certain types of non-Hodgkin lymphoma (NHL) treated with fludarabine-containing chemotherapy (with or without rituximab), or those diagnosed with T-cell–activating autoimmune conditions, have an increased risk of developing cutaneous melanoma. The findings from this large-scale, population-based study, now online ahead of print in the Journal of Clinical Oncology (doi: 10.1200/JCO.2014.60.2094), thus identify high-risk survivors of NHL who would benefit most from regular full skin examinations to maximize opportunities for early detection of cutaneous melanoma.